Posted by Michael Wonder on 24 Feb 2026
Wegovy and Mounjaro for weight loss not funded
24 February 2026 - Medsafe has recently approved two new medicines as suitable to support weight management.
PHARMAC's role is to decide whether medicines will be publicly funded.
PHARMAC has received three applications to fund semaglutide for the following conditions:
- Weight management for people with a body mass index of 30 kg/m² or more with at least one weight-related health condition
- Insufficiently controlled type 2 diabetes mellitus
- Cardiovascular disease with a body mass index of 27 kg/m² or more
PHARMAC has received one application to fund tirzepatide for patients with insufficiently controlled type 2 diabetes mellitus.
